Alliance for Aging Research

Based in DC

🤖

AI Overview

With $1.3M in lobbying spend across 43 quarterly filings, Alliance for Aging Research is a significant lobbying presence. Their lobbying covers 12 issue areas. Active from 2018 to 2025.

$1.3M

Total Spend

Years Active

Firms Hired

Lobbyists Deployed

Issues Lobbied

Spending Trend

View as table

Year	Lobbying Spend
2018	$0
2019	$0
2020	$0
2021	$0
2022	$0
2023	$0
2024	$818K
2025	$530K

Issues Lobbied

Budget/Appropriations Medicare/Medicaid Health Issues MED Advertising Taxation Retirement Environment Pharmacy Postal Small Business Trade

Lobbying Firms

Alliance for Aging Research

Lobbyists

Ryne Carney Ellen Jenkins Michael Ward Adina Lasser Scott Frey

Government Agencies Targeted

These are the government entities that Alliance for Aging Research disclosed contacting in their lobbying filings.

Agency for Healthcare Research & Quality (AHRQ)Centers For Disease Control & Prevention (CDC)Centers For Medicare and Medicaid Services (CMS)Food & Drug Administration (FDA)Health & Human Services, Dept of (HHS)HOUSE OF REPRESENTATIVESNatl Institutes of Health (NIH)SENATEAdministration for Children & Families (ACF)Corporation for Natl & Community ServiceFederal Transit Administration (FTA)Housing & Urban Development, Dept of (HUD)Justice, Dept of (DOJ)Social Security Administration (SSA)White House OfficePresident of the U.S.Treasury, Dept ofVeterans Affairs, Dept of (VA)Small Business Administration (SBA)Office of Management & Budget (OMB)+3 more

View all agency pressure data →

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Budget/Appropriations, Medicare/Medicaid, Health Issues, MED, Advertising and 7 more

Support increased funding for federal antimicrobial resistance initiatives (S.2469) STAAR and the reauthorization of the Pandemic and All-Hazards Preparedness Act (not yet introduced)

Support for CDC'

Short term limited duration plans in Medicare; Medicare extenders as part of the CR

Antimicrobial resistance funding and research; heart disease; appropriations for NIH/FDA/AHRQ/CDC; Medicare extenders; Short term limited duration plans (STLDP) in Medicare

Increased research for antimicrobial resistance

Antimicrobial resistance funding and research; heart disease; appropriations for NIH/FDA/AHRQ/CDC; Short term limited duration plans (STLDP) in Medicare; FDA guidance on Alzheimer's Disease Research;